Management radiated optimism during the conference call pointing to the strong order backlog and hopes in the pickup procedures. The Q4 figures were impacted by the ongoing dearth of elective procedures burdening the Diagnostic margin and Advanced Therapies suffering from higher costs for Corindus. Nevertheless, the FCF was strongly higher. These results beat our cautious expectations and were slightly above consensus. The dividend proposal was however below our forecast.